Follow the people · Insider
Jean Jacques Bienaime
Jean Jacques Bienaime files insider transactions with the SEC as a director of Keros Therapeutics (KROS). We hold 14 disclosed purchases and sales filed since 4 January 2006, 4 of them in the last 90 days.
- Files forKROS
- Disclosed buys and sells14 in all, 4 in the last 90 days
- Last disclosure19 August 2026
Positions held
9 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 June 2024 — 17 August 2026Director · Keros Therapeutics (KROS)12 Form 4 lines · source: SEC Form 4
- Filed 26 May 2026 — 14 August 2026Director · Ascendis Pharma A/S (ASND)7 Form 4 lines · source: SEC Form 4
- Filed 7 November 2023 — 10 June 2026Director · Immunome (IMNM)19 Form 4 lines · source: SEC Form 4
- Filed 20 January 2015 — 8 June 2026Director · Incyte (INCY)58 Form 4 lines · source: SEC Form 4
- Filed 3 January 2006 — 20 May 2024Chief Executive Officer · Biomarin Pharmaceutical (BMRN)1,385 Form 4 lines · source: SEC Form 4
- Filed 23 April 2001 — 24 September 2018Director · Vital Therapies (VTL)16 Form 4 lines · source: SEC Form 4
- Filed 6 April 2012 — 29 September 2014Director · Intermune (ITMN)19 Form 4 lines · source: SEC Form 4
- Filed 22 May 2013 — 16 May 2014Director · Portola Pharmaceuticals (PTLA)6 Form 4 lines · source: SEC Form 4
- Filed 7 May 2007 — 7 February 2012Director · NeurogesX (NGSX)77 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- was granted 12,517 shares of Incyte (a derivative holding)SEC Form 414 June 2024Non Qualfied Stock Option (right to buy) · traded 12 June 2024 · filed 14 June 2024
- was granted 2,830 shares of IncyteSEC Form 414 June 2024Common Stock · traded 12 June 2024 · filed 14 June 2024
- had shares withheld for tax on 1,202 shares of Biomarin PharmaceuticalSEC Form 421 May 2024Common Stock · traded 20 May 2024 · filed 21 May 2024
- exercised options over 20,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 413 May 2024Stock Option (Right to Buy Common Stock) · traded 9 May 2024 · filed 13 May 2024
- exercised options over 20,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 413 May 2024Stock Option (Right to Buy Common Stock) · traded 10 May 2024 · filed 13 May 2024
- exercised options over 20,000 shares of Biomarin PharmaceuticalSEC Form 413 May 2024Common Stock · traded 9 May 2024 · filed 13 May 2024
- ▼ sold on the open market 20,000 shares of Biomarin PharmaceuticalSEC Form 413 May 2024Common Stock · traded 9 May 2024 · filed 13 May 2024
- exercised options over 20,000 shares of Biomarin PharmaceuticalSEC Form 413 May 2024Common Stock · traded 10 May 2024 · filed 13 May 2024
- ▼ sold on the open market 20,000 shares of Biomarin PharmaceuticalSEC Form 413 May 2024Common Stock · traded 10 May 2024 · filed 13 May 2024
- exercised options over 20,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 415 April 2024Stock Option (Right to Buy Common Stock) · traded 11 April 2024 · filed 15 April 2024
- exercised options over 20,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 415 April 2024Stock Option (Right to Buy Common Stock) · traded 12 April 2024 · filed 15 April 2024
- exercised options over 20,000 shares of Biomarin PharmaceuticalSEC Form 415 April 2024Common Stock · traded 11 April 2024 · filed 15 April 2024
- ▼ sold on the open market 20,000 shares of Biomarin PharmaceuticalSEC Form 415 April 2024Common Stock · traded 11 April 2024 · filed 15 April 2024
- exercised options over 20,000 shares of Biomarin PharmaceuticalSEC Form 415 April 2024Common Stock · traded 12 April 2024 · filed 15 April 2024
- ▼ sold on the open market 20,000 shares of Biomarin PharmaceuticalSEC Form 415 April 2024Common Stock · traded 12 April 2024 · filed 15 April 2024
- had shares withheld for tax on 85,209 shares of Biomarin PharmaceuticalSEC Form 419 March 2024Common Stock · traded 15 March 2024 · filed 19 March 2024
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 47 March 2024Common Stock · traded 5 March 2024 · filed 7 March 2024
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 47 March 2024Common Stock · traded 6 March 2024 · filed 7 March 2024
- was granted 82,700 shares of Biomarin PharmaceuticalSEC Form 429 February 2024Common Stock · traded 27 February 2024 · filed 29 February 2024
- was granted 35,975 shares of Biomarin PharmaceuticalSEC Form 429 February 2024Common Stock · traded 27 February 2024 · filed 29 February 2024
- was granted 24,926 shares of Biomarin PharmaceuticalSEC Form 429 February 2024Common Stock · traded 27 February 2024 · filed 29 February 2024
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 429 February 2024Common Stock · traded 27 February 2024 · filed 29 February 2024
- gave away 1,000 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 6 February 2023 · filed 12 February 2024
- gave away 4,400 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 7 February 2023 · filed 12 February 2024
- gave away 200 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 9 February 2023 · filed 12 February 2024
- exercised options over 15,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 412 February 2024Stock Option (Right to Buy Common Stock) · traded 8 February 2024 · filed 12 February 2024
- exercised options over 15,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 412 February 2024Stock Option (Right to Buy Common Stock) · traded 9 February 2024 · filed 12 February 2024
- received in a small acquisition of 40 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 18 January 2024 · filed 12 February 2024
- exercised options over 15,000 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- ▼ sold on the open market 15,000 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- exercised options over 15,000 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 9 February 2024 · filed 12 February 2024
- ▼ sold on the open market 15,000 shares of Biomarin PharmaceuticalSEC Form 412 February 2024Common Stock · traded 9 February 2024 · filed 12 February 2024
- exercised options over 10,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 411 January 2024Stock Option (Right to Buy Common Stock) · traded 9 January 2024 · filed 11 January 2024
- exercised options over 10,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 411 January 2024Stock Option (Right to Buy Common Stock) · traded 10 January 2024 · filed 11 January 2024
- received in a small acquisition of 50 shares of Biomarin PharmaceuticalSEC Form 411 January 2024Common Stock · traded 8 January 2024 · filed 11 January 2024
- exercised options over 10,000 shares of Biomarin PharmaceuticalSEC Form 411 January 2024Common Stock · traded 9 January 2024 · filed 11 January 2024
- ▼ sold on the open market 10,000 shares of Biomarin PharmaceuticalSEC Form 411 January 2024Common Stock · traded 9 January 2024 · filed 11 January 2024
- exercised options over 10,000 shares of Biomarin PharmaceuticalSEC Form 411 January 2024Common Stock · traded 10 January 2024 · filed 11 January 2024
- ▼ sold on the open market 10,000 shares of Biomarin PharmaceuticalSEC Form 411 January 2024Common Stock · traded 10 January 2024 · filed 11 January 2024
- exercised options over 10,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 422 December 2023Stock Option (Right to Buy Common Stock) · traded 21 December 2023 · filed 22 December 2023
- exercised options over 10,000 shares of Biomarin PharmaceuticalSEC Form 422 December 2023Common Stock · traded 21 December 2023 · filed 22 December 2023
- ▼ sold on the open market 10,000 shares of Biomarin PharmaceuticalSEC Form 422 December 2023Common Stock · traded 21 December 2023 · filed 22 December 2023
- received in a small acquisition of 10 shares of Biomarin PharmaceuticalSEC Form 412 December 2023Common Stock · traded 4 October 2023 · filed 12 December 2023
- was granted 2,370 shares of Biomarin PharmaceuticalSEC Form 412 December 2023Common Stock · traded 1 December 2023 · filed 12 December 2023
- ▼ sold on the open market 4,000 shares of Biomarin PharmaceuticalSEC Form 49 August 2023Common Stock · traded 7 August 2023 · filed 9 August 2023
- ▼ sold on the open market 6,000 shares of Biomarin PharmaceuticalSEC Form 49 August 2023Common Stock · traded 8 August 2023 · filed 9 August 2023
- ▲ bought on the open market 4,000 shares of Vital TherapiesSEC Form 411 September 2015Common Stock · traded 9 September 2015 · filed 11 September 2015
- ▲ bought on the open market 2,000 shares of Vital TherapiesSEC Form 411 September 2015Common Stock · traded 9 September 2015 · filed 11 September 2015
- ▲ bought on the open market 2,000 shares of Vital TherapiesSEC Form 411 September 2015Common Stock · traded 9 September 2015 · filed 11 September 2015
- ▲ bought on the open market 6,000 shares of Vital TherapiesSEC Form 411 September 2015Common Stock · traded 10 September 2015 · filed 11 September 2015
- was granted 25,000 shares of Incyte (a derivative holding)SEC Form 422 January 2015Non-Qualified Stock Option (right to buy) · traded 20 January 2015 · filed 22 January 2015
- was granted 5,000 shares of Incyte (a derivative holding)SEC Form 422 January 2015Non-Qualified Stock Option (right to buy) · traded 20 January 2015 · filed 22 January 2015
- exercised options over 20,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 43 May 2012Stock Option (right to buy) · traded 1 May 2012 · filed 3 May 2012
- exercised options over 10,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 43 May 2012Stock Option (right to buy) · traded 2 May 2012 · filed 3 May 2012
- was granted 1,098 shares of Biomarin PharmaceuticalSEC Form 43 May 2012Common Stock · traded 30 April 2012 · filed 3 May 2012
- exercised options over 20,000 shares of Biomarin PharmaceuticalSEC Form 43 May 2012Common Stock · traded 1 May 2012 · filed 3 May 2012
- exercised options over 20,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 430 April 2012Stock Option (right to buy) · traded 27 April 2012 · filed 30 April 2012
- exercised options over 20,000 shares of Biomarin PharmaceuticalSEC Form 430 April 2012Common Stock · traded 27 April 2012 · filed 30 April 2012
- ▼ sold on the open market 20,000 shares of Biomarin PharmaceuticalSEC Form 430 April 2012Common Stock · traded 27 April 2012 · filed 30 April 2012
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 430 April 2012Common Stock · traded 27 April 2012 · filed 30 April 2012
- exercised options over 15,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 413 March 2012Stock Option (right to buy) · traded 9 March 2012 · filed 13 March 2012
- exercised options over 15,000 shares of Biomarin PharmaceuticalSEC Form 413 March 2012Common Stock · traded 9 March 2012 · filed 13 March 2012
- ▼ sold on the open market 15,000 shares of Biomarin PharmaceuticalSEC Form 413 March 2012Common Stock · traded 9 March 2012 · filed 13 March 2012
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 49 March 2012Common Stock · traded 8 March 2012 · filed 9 March 2012
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 41 March 2012Common Stock · traded 29 February 2012 · filed 1 March 2012
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 428 February 2012Common Stock · traded 24 February 2012 · filed 28 February 2012
- ▼ sold on the open market 3,000 shares of Biomarin PharmaceuticalSEC Form 428 February 2012Common Stock · traded 27 February 2012 · filed 28 February 2012
- ▼ sold on the open market 5,000 shares of Biomarin PharmaceuticalSEC Form 424 February 2012Common Stock · traded 23 February 2012 · filed 24 February 2012
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 430 September 2011Common Stock · traded 28 September 2011 · filed 30 September 2011
- exercised options over 2,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 431 August 2011Stock Option (right to buy) · traded 30 August 2011 · filed 31 August 2011
- exercised options over 2,000 shares of Biomarin PharmaceuticalSEC Form 431 August 2011Common Stock · traded 30 August 2011 · filed 31 August 2011
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 431 August 2011Common Stock · traded 30 August 2011 · filed 31 August 2011
- exercised options over 2,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 422 August 2011Stock Option (right to buy) · traded 19 August 2011 · filed 22 August 2011
- exercised options over 2,000 shares of Biomarin PharmaceuticalSEC Form 422 August 2011Common Stock · traded 19 August 2011 · filed 22 August 2011
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 422 August 2011Common Stock · traded 19 August 2011 · filed 22 August 2011
- exercised options over 3,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 416 August 2011Stock Option (right to buy) · traded 12 August 2011 · filed 16 August 2011
- exercised options over 3,000 shares of Biomarin PharmaceuticalSEC Form 416 August 2011Common Stock · traded 12 August 2011 · filed 16 August 2011
- ▼ sold on the open market 3,000 shares of Biomarin PharmaceuticalSEC Form 416 August 2011Common Stock · traded 12 August 2011 · filed 16 August 2011
- exercised options over 4,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 44 August 2011Stock Option (right to buy) · traded 2 August 2011 · filed 4 August 2011
- exercised options over 4,000 shares of Biomarin PharmaceuticalSEC Form 44 August 2011Common Stock · traded 2 August 2011 · filed 4 August 2011
- ▼ sold on the open market 4,000 shares of Biomarin PharmaceuticalSEC Form 44 August 2011Common Stock · traded 2 August 2011 · filed 4 August 2011
- ▼ sold on the open market 4,000 shares of Biomarin PharmaceuticalSEC Form 44 August 2011Common Stock · traded 2 August 2011 · filed 4 August 2011
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 418 July 2011Common Stock · traded 14 July 2011 · filed 18 July 2011
- exercised options over 5,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 48 June 2011Restricted Stock Units · traded 7 June 2010 · filed 8 June 2011
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 48 June 2011Common Stock · traded 6 June 2011 · filed 8 June 2011
- exercised options over 5,000 shares of Biomarin PharmaceuticalSEC Form 48 June 2011Common Stock · traded 7 June 2011 · filed 8 June 2011
- ▼ sold on the open market 710 shares of Biomarin PharmaceuticalSEC Form 42 June 2011Common Stock · traded 31 May 2011 · filed 2 June 2011
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 431 May 2011Common Stock · traded 25 May 2011 · filed 31 May 2011
- ▼ sold on the open market 290 shares of Biomarin PharmaceuticalSEC Form 431 May 2011Common Stock · traded 27 May 2011 · filed 31 May 2011
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 426 May 2011Common Stock · traded 25 May 2011 · filed 26 May 2011
- exercised options over 7,500 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 424 May 2011Restricted Stock Units · traded 20 May 2011 · filed 24 May 2011
- exercised options over 7,500 shares of Biomarin PharmaceuticalSEC Form 424 May 2011Common Stock · traded 20 May 2011 · filed 24 May 2011
- was granted 280,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 416 May 2011Stock Option (right to buy) · traded 12 May 2011 · filed 16 May 2011
- was granted 36,000 shares of Biomarin PharmaceuticalSEC Form 416 May 2011Common Stock · traded 12 May 2011 · filed 16 May 2011
- ▼ sold on the open market 400 shares of Biomarin PharmaceuticalSEC Form 412 May 2011Common Stock · traded 10 May 2011 · filed 12 May 2011
- ▼ sold on the open market 200 shares of Biomarin PharmaceuticalSEC Form 49 May 2011Common Stock · traded 5 May 2011 · filed 9 May 2011
- exercised options over 3,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 45 May 2011Stock Option (right to buy) · traded 3 May 2011 · filed 5 May 2011
- exercised options over 1,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 45 May 2011Stock Option (right to buy) · traded 4 May 2011 · filed 5 May 2011
- was granted 1,826 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 29 April 2011 · filed 5 May 2011
- exercised options over 3,000 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 3 May 2011 · filed 5 May 2011
- ▼ sold on the open market 3,000 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 3 May 2011 · filed 5 May 2011
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 3 May 2011 · filed 5 May 2011
- exercised options over 1,000 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 4 May 2011 · filed 5 May 2011
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 4 May 2011 · filed 5 May 2011
- ▼ sold on the open market 1,700 shares of Biomarin PharmaceuticalSEC Form 45 May 2011Common Stock · traded 4 May 2011 · filed 5 May 2011
- ▼ sold on the open market 3,500 shares of Biomarin PharmaceuticalSEC Form 419 January 2011Common Stock · traded 18 January 2011 · filed 19 January 2011
- exercised options over 2,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 413 December 2010Stock Option (right to buy) · traded 6 December 2010 · filed 13 December 2010
- exercised options over 2,000 shares of Biomarin PharmaceuticalSEC Form 413 December 2010Common Stock · traded 6 December 2010 · filed 13 December 2010
- ▼ sold on the open market 2,000 shares of Biomarin PharmaceuticalSEC Form 413 December 2010Common Stock · traded 6 December 2010 · filed 13 December 2010
- exercised options over 1,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 413 December 2010Stock Option (right to buy) · traded 13 December 2010 · filed 13 December 2010
- exercised options over 1,000 shares of Biomarin PharmaceuticalSEC Form 413 December 2010Common Stock · traded 13 December 2010 · filed 13 December 2010
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 413 December 2010Common Stock · traded 13 December 2010 · filed 13 December 2010
- exercised options over 1,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 47 December 2010Stock Option (right to buy) · traded 6 December 2010 · filed 7 December 2010
- exercised options over 1,000 shares of Biomarin PharmaceuticalSEC Form 47 December 2010Common Stock · traded 6 December 2010 · filed 7 December 2010
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 47 December 2010Common Stock · traded 6 December 2010 · filed 7 December 2010
- exercised options over 1,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 423 November 2010Stock Option (right to buy) · traded 23 November 2010 · filed 23 November 2010
- exercised options over 1,000 shares of Biomarin PharmaceuticalSEC Form 423 November 2010Common Stock · traded 23 November 2010 · filed 23 November 2010
- ▼ sold on the open market 1,000 shares of Biomarin PharmaceuticalSEC Form 423 November 2010Common Stock · traded 23 November 2010 · filed 23 November 2010
- exercised options over 1,000 shares of Biomarin Pharmaceutical (a derivative holding)SEC Form 422 November 2010Stock Option (right to buy) · traded 8 November 2010 · filed 22 November 2010
- exercised options over 1,000 shares of Biomarin PharmaceuticalSEC Form 422 November 2010Common Stock · traded 18 November 2010 · filed 22 November 2010
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.